Body Protection Compound

BPC-157

Body Protection Compound 157 • 15-Amino-Acid Repair Peptide

BPC-157 is a synthetic peptide derived from a protective protein fragment found in gastric juice. It is researched primarily in animal and laboratory models for tendon, ligament, muscle, gastrointestinal, wound, bone, and nerve repair; controlled human evidence remains extremely limited.

Tissue Repair Tendon & Ligament Gut Research WADA Prohibited

Protocol Snapshot

Quick reference before the deep dive

Verified Vendors

BPC-157

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Community Dose

250–500mcg

Daily total commonly reported in peptide communities; not established by a human dose-finding trial.

Cycle Length

4–8 weeks

Common community convention for active recovery tracking.

Routes

SubQ / Oral

Neither route has a validated human therapeutic protocol.

Evidence

Preclinical

Extensive animal research, but very limited human evidence.

Peptide Grade

GradeB

Broad preclinical repair findings and unusually strong community adoption make BPC-157 a practical injury and gut-research tool, but the near absence of controlled human evidence is the decisive limitation.

Research Community Safety

Strong preclinical repair signal and broad community use, limited by the absence of robust controlled human trials.

Foundation

Research context, mechanisms, and practical use cases

What Is BPC-157?

BPC-157 stands for Body Protection Compound 157. It is a synthetic sequence of 15 amino acids derived from a protective protein fragment associated with gastric juice.

The compound has been studied for decades across animal and laboratory models involving tendon, ligament, muscle, bone, gastrointestinal tissue, wounds, and peripheral nerves. That breadth explains its reputation as a general repair peptide.

Human Data Reality Check

The evidence base is overwhelmingly preclinical. Limited human reports and pilot work do not establish an effective dose, route, treatment duration, or long-term safety profile.

How It May Work

BPC-157 appears to influence several repair pathways rather than acting through one confirmed human mechanism.

Blood-Flow Signaling

Preclinical studies suggest modulation of VEGF-related signaling, angiogenesis, and tissue perfusion.

Nitric Oxide System

Animal research suggests interaction with nitric-oxide pathways involved in vascular function and tissue response.

Cell Migration

Laboratory models report effects on fibroblast survival, migration, and connective-tissue repair activity.

Gastrointestinal Protection

Gastric and intestinal injury models are a major part of the compound’s preclinical research history.

BPC-157 Research Benefits

These potential benefits are supported mainly by animal or laboratory data and should not be read as established human treatment outcomes.

Tendon & Ligament Repair

Animal studies report improved tendon healing, fibroblast activity, and connective-tissue organization.

Muscle Recovery

Preclinical injury models report improvements in muscle structure, function, and healing.

Gut Protection

Animal models include ulcers, inflammatory injury, and NSAID-associated gastrointestinal damage.

Nerve Research

Peripheral-nerve models suggest possible neuroprotective and regeneration-related effects.

Protocol Planning

Dosing, cycling, and preparation

BPC-157 Dosing Protocol

No human dose-finding trial has established an optimal dose, frequency, route, or cycle. The ranges below describe community practice.

Subcutaneous — Community Practice

Daily Total

250–500mcg

Frequency

Once daily or divided into two daily doses

Timing

Morning and/or evening; no fasting convention is required

Cycle

4–8 weeks, with response tracked throughout

Route Context

SubQ

Most commonly reported for musculoskeletal recovery

Oral

Commonly discussed for gastrointestinal goals, but human bioavailability and comparative efficacy remain uncertain

Local Injection

Human evidence has not established that injection near an injury is superior to standard subcutaneous administration

BPC-157 Reconstitution

The example below uses a 10mg vial with 2mL of bacteriostatic water.

10mg Vial

BAC Water

2mL

Concentration

5mg/mL

250mcg

5 units on a U-100 syringe

500mcg

10 units on a U-100 syringe

Handling

Add bacteriostatic water to the vial, swirl gently if needed, and do not shake

Storage

Refrigerate after reconstitution

Reconstitution Calculator

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Users frequently describe reduced pain or irritation during recovery from tendon, ligament, muscle, and overuse injuries.
Some report early symptom changes within 1–2 weeks, followed by gradual improvements in movement or training tolerance.
BPC-157 plus TB-500 is the most frequently discussed community combination for musculoskeletal recovery.

Negative Reports

Some users report no meaningful change, especially with longstanding structural injuries.
Oral reports are mixed, and many users consider the results less predictable than injectable use.
Injection-site redness, swelling, or discomfort is among the more common practical complaints.

Stacking & Synergy

Potential BPC-157 pairings and tracking context

These are mechanistic or community-discussed pairings, not validated combination protocols.

BPC-157 + TB-500

The “Wolverine Stack” combines two compounds discussed around different repair pathways. Human combination data is absent.

BPC-157 + KPV

A theoretical pairing for gastrointestinal or inflammation-focused tracking; no controlled combination studies exist.

BPC-157 + GHK-Cu

Community rationale centers on repair signaling plus collagen and extracellular-matrix support.

Free with login

Track in Journal

Track BPC-157 with the recovery markers that matter most for this compound.

Dose, route, timing, injection site, and cycle day.
Pain level, swelling, tenderness, and symptom trend.
Range of motion, strength, training tolerance, and functional milestones.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

BPC-157 Side Effects

In Published Research

Preclinical toxicity research has not revealed major acute toxicities across the studied animal models. In one intramuscular toxicity study, no acute toxicity or histopathological organ changes were reported at 20mg/kg in rats and 10mg/kg in dogs. Those animal results do not establish safety for human subcutaneous use.

A 2025 pilot study administered 10mg and then 20mg intravenous infusions to two healthy adults. No adverse effects or clinically meaningful changes in the measured heart, liver, kidney, thyroid, glucose, vital-sign, or blood markers were reported. A study of only two previously exposed participants cannot establish a human safety profile.

FDA states that compounded drugs containing BPC-157 may pose immunogenicity risks and present peptide-impurity and active-ingredient-characterization concerns. FDA has identified no or only limited safety information for proposed routes of administration.

What Users Report

Common Reports

Injection-site redness, swelling, or mild pain.
Mild nausea, especially at daily totals above 500mcg.
Dizziness, fatigue, or drowsiness.

Less Common Reports

Anxiety or mood changes.
Heart palpitations or headaches.
Insomnia, particularly with late-day dosing.
Loss of appetite.

Community reports often describe these effects as dose-related and temporary, but that pattern has not been confirmed in controlled human research.

BPC-157 Contraindications and Precautions

Do Not Use If You Have

Active cancer or tumors.
A history of malignancy without clearance from the treating oncologist.
Known hypersensitivity to BPC-157 or any formulation component.

Use Caution With

Pregnancy or breastfeeding because no adequate safety data exists.
Liver or kidney impairment.
Cardiovascular conditions.
Precancerous conditions or unresolved masses.
Any serious condition requiring medical supervision.

Drug Interactions

NSAIDs: the available preclinical literature is mixed and does not establish a clinically meaningful human interaction.
No well-established drug-interaction profile exists because controlled human data is insufficient.

Regulatory Status

BPC-157 is not FDA approved for human therapeutic use.
FDA placed BPC-157 among Category 2 bulk substances raising significant safety risks in September 2023. FDA’s current safety-risk page continues to flag BPC-157, and its 503A compounding status is under active agency review in 2026.
BPC-157 has been prohibited at all times by WADA under S0 Non-Approved Substances since 2022 and remains listed in 2026.

Athletes subject to anti-doping rules should not use BPC-157.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

This compound, especially when discussing the Wolverine stack, is so popular and the reasons are valid. Some of the claims about repairing fully reptured tendons are definitely out there and we think that might be a bit out of reach. That said, this thing works and for what it is works really well. Our rat followed just the morning protocol for a bit of tennis elbow, now pickleball elbow, and there was gradule improvement into a full symptom free response in roughly 15 days. The issue has not come back either, whereas prior to the administration of BPC-157 the injury would reaggravate. BPC-157 or its uncle, affectionately known as the Wolverine blend should be a part of any researchers toolkit or kept in freezer storage for when the need arises. The next leg of research will be to pair the Woverine blend with Cartalax.